Pipeline—creating tomorrow's vaccines today

The world urgently needs new tools to help solve some of our greatest infectious disease challenges. Novavax is applying our unique technology to address current and emerging threats.

Novavax continually conducts clinical trials, investigations, gathering of real-world evidence, and development of vaccines to address public health threats. Our scientists in our research and development (R&D) programs are committed to the efficient delivery of new vaccines while maintaining the safety of patients who take part in our trials.

Our pipeline

Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities.

Our Matrix-M adjuvant technology

Matrix-M adjuvant

Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.

Learn more about our technology platform

Learn more about our disease areas of focus

Vaccines in Novavax Pipeline and Status
Therapeutic area
Candidate
Technology
Phase of trial
Authorized use
   
Preclinical
Phase 1
Phase 2
Phase 3
 
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine (NVX-C0V2373)
Matrix-M™ adjuvant
    
 
Authorized*
Respiratory diseases
COVID-19
Novavax COVID-19 Omicron vaccine
Matrix-M™ adjuvant
 
Preclinical
   
Respiratory diseases
Seasonal influenza
NanoFlu
Matrix-M™ adjuvant
   
 
Phase 3
in progress
Respiratory diseases
COVID-19 + seasonal influenza
Novavax COVID-NanoFlu combination candidate
Matrix-M™ adjuvant
  
 
Phase 1/2
 
Respiratory diseases
Respiratory syncytial virus (RSV)
ResVax for infants via maternal immunization
   
 
Phase 3
Respiratory diseases
Respiratory syncytial virus (RSV)
RSV F vaccine for children between 2-6 years old
 
 
Phase 1
  
Respiratory diseases
Respiratory syncytial virus (RSV)
RSV F vaccine for adults 60+ years old
Matrix-M™ adjuvant
 
 
Phase 1
  
Respiratory diseases
Middle East Respiratory Syndrome (MERS)
MERS vaccine
 
Preclinical
   
Respiratory diseases
Severe Acute Respiratory Syndrome (SARS)
SARS vaccine
 
Preclinical
   
Parasitic diseases
Malaria
R21
Matrix-M™ adjuvant
  
 
Phase 2b
in progress
 
Parasitic diseases
Ebola
Ebola GP vaccine
Matrix-M™ adjuvant
 
 
Phase 1
  
Respiratory diseases
COVID-19
Novavax COVID-19 vaccine (NVX-C0V2373)
 
Authorized*
Matrix-M™ adjuvant
Respiratory diseases
COVID-19
Novavax COVID-19 Omicron vaccine
 
Preclinical
Matrix-M™ adjuvant
Respiratory diseases
Seasonal influenza
NanoFlu
 
Phase 3
in progress
Matrix-M™ adjuvant
Respiratory diseases
COVID-19 + seasonal influenza
Novavax COVID-NanoFlu combination candidate
 
Phase 1/2
Matrix-M™ adjuvant
Respiratory diseases
Respiratory syncytial virus (RSV)
ResVax for infants via maternal immunization
 
Phase 3
RSV F vaccine for children between 2-6 years old
 
Phase 1
RSV F vaccine for adults 60+ years old
 
Phase 1
Matrix-M™ adjuvant
Respiratory diseases
Middle East Respiratory Syndrome (MERS)
MERS vaccine
 
Preclinical
Respiratory diseases
Severe Acute Respiratory Syndrome (SARS)
SARS vaccine
 
Preclinical
Parasitic diseases
Malaria
R21
 
Phase 2b
in progress
Matrix-M™ adjuvant
Parasitic diseases
Ebola
Ebola GP vaccine
 
Phase 1
Matrix-M™ adjuvant
*Authorized for use in several countries.
This trial did not meet its primary endpoint.

Investigational vaccine and trial sponsored by University of Oxford in collaboration with Serum Institute of India with Matrix-M adjuvant.

Science & Technology

From the diseases that we're focused on to the details of our scientific approach

Science & Technology

Source in-depth information, including clinical trial protocols

Who we are

Novavax is powered by global collaborations